State law can’t compel ‘patent dance’, rules Federal Circuit
15-12-2017
DoJ sues company for selling unapproved drugs and supplements
21-02-2017
FTC and DoJ update antitrust guidelines
18-01-2017
traveler1116 / iStockphoto.com
The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
US Department of Justice, DoJ, SCOTUS, patent, patent dance, BPCIA, FDA, IPR, biosimilar, Neupogen, Amgen, Sandoz, US Court of Appeals for the Federal Circ
